Banca Transilvania is supporting the investment plans of Antibiotice Iași, the largest generic drug manufacturer with majority Romanian shareholding, through a EUR 67 million financing. The funding will support two strategic projects that are essential to Romania’s pharmaceutical industry:

• Production, packaging, and storage capacity for sterile products, solutions, and topical products is one of the most significant investment projects developed by Antibiotice Iași in recent years. It will strengthen the company’s strategic position in the topical products and sterile solutions segment in Romania and abroad by expanding its portfolio of essential medicines for hospitals. The project will also increase healthcare system resilience and improve the availability of essential therapeutic solutions, with a direct impact on patient care. It was launched with funding from the European Investment Bank in Romania through the InvestEU program and also benefits from non-reimbursable funds granted by the Ministry of Finance.
  
  
• The INOVA a+ research and development center and the new critical medicines production facility represent a strategic investment with major relevance for the health security of Romania and Europe. The project will strengthen Romania’s capacity to produce critical medicines locally, reduce dependence on external supply chains, and support the European Union’s objectives for strategic autonomy in the health sector. It will also reinforce Antibiotice’s long-term growth prospects by expanding innovation capabilities, broadening the product portfolio, and increasing competitiveness in international markets. The project includes a grant component provided by the Ministry of Investments and European Projects through the STEP (Strategic Technologies for Europe Platform) program.
  
  

This financing marks a new phase in the collaboration between the two companies and supports the implementation of strategically important investments for Romania’s pharmaceutical industry.

We are honored to support Antibiotice’s development plans by financing strategic projects that benefit both the company and the entire Romanian healthcare ecosystem. This financing reaffirms Banca Transilvania’s commitment to supporting Romania’s leading companies, which generate value, innovation, and impact in people’s lives.

Cosmin Călin
Senior Executive Director, Large Corporates, Structured Finance, and Factoring
Banca Transilvania

This funding strengthens Antibiotice Iași’s ability to accelerate strategic investments and support its long-term growth objectives, both in the Romanian market and internationally. The partnership with Banca Transilvania reflects confidence in our development strategy and in the company’s potential to generate sustainable value for the healthcare system, partners, and shareholders.

Ioan Nani
CEO
Antibiotice

Both Banca Transilvania and Antibiotice are part of the BET index of the Bucharest Stock Exchange, which includes the 20 most actively traded companies listed on the BSE. Financing partnerships such as the one announced today help accelerate investment in a strategic sector for Romania, generating positive effects across both the economy and the healthcare system.